Romosozumab and Teriparatide Efficacy and Safety Compared for Postmenopausal Osteoporosis in Meta-Analyses

Osteoporosis, characterized by reduced bone density and increased fracture risk, significantly impacts postmenopausal women. It is also a critical risk factor for complications following spinal fusion surgery. Current treatments aim to prevent fractures and improve bone mineral density. Romosozumab, a novel sclerostin inhibitor, promotes bone formation and reduces bone resorption, while teriparatide, a parathyroid hormone (PTH) analog, primarily stimulates osteoblast activity. Understanding their comparative efficacy and safety is crucial for optimizing treatment strategies in high-risk patients.

Researchers conducted a systematic review with meta-analyses to compare the efficacy and safety profiles of romosozumab against teriparatide in postmenopausal women with osteoporosis. A comprehensive literature search was performed across major databases including Medline, the Cochrane Library, CRD, and LILACS, covering publications up to November 2023. The review specifically included systematic reviews that incorporated meta-analyses, focusing on studies that assessed the use of these two anti-osteoporosis agents.

The systematic review aimed to synthesize existing evidence regarding the comparative efficacy and safety of romosozumab versus teriparatide for postmenopausal osteoporosis. While specific numerical outcomes were not detailed in the provided abstract, the review's objective was to summarize findings related to key clinical endpoints. These typically include changes in bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck, as well as the incidence of new vertebral and non-vertebral fractures. Safety assessments would encompass the reporting of adverse events (AEs), serious adverse events (SAEs), and specific side effects associated with each drug, such as injection site reactions or hypercalcemia. The meta-analyses would have aggregated data from multiple studies to provide a more robust estimate of treatment effects and risks.

The primary focus was to provide a comprehensive overview of how romosozumab's dual mechanism of action (bone formation and anti-resorption) compares to teriparatide's anabolic effects in a real-world evidence synthesis.